Shares of Relypsa Inc (NASDAQ: RLYP) were volatile Thursday morning. The company is the central focus of The Street Sweeper's latest short thesis. The Street Sweeper's Sony Colberg offered eight ...

As hype around new treatments for the blood disorder hyperkalemia continues unabated after AstraZeneca's $2.7 billion buyout of ZS Pharma last year, Relypsa ($RLYP ...

Galenica Group and Relypsa Inc (NYSE: RLYP) revealed that they reached a definitive agreement by which the former would acquire Relypsa for $32.00 a share or a total of about $1.53 billion. According ...

What:Relypsa (NASDAQ: RLYP) , a biopharmaceutical company developing gastrointestinal medicines, saw its shares surge 58% higher at the opening bell today on the news that the Swiss-based Galenica ...

Add Yahoo as a preferred source to see more of our stories on Google. By Anjali Rao Koppala (Reuters) - The U.S. Food and Drug Administration approved Relypsa Inc's drug to treat potentially fatal ...

Relypsa, Inc. 's RLYP lead candidate, Veltassa gained approval in the U.S. for the treatment of hyperkalemia. Shares which should have been up with the positive news were, however, down 27.2% due to ...

SOURCE: FLICKR USER STEVE JURVETSON. What:Swirling rumors that an acquirer might step up to buy the company caused shares inRelypsa, to soar 67.6% higher today. So what: The company has been the ...

Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa significantly reduced blood potassium and kept ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million.

Solution/Product: Patiromer, or RLY5016, is a non-absorbed oral potassium binder being developed for the treatment of hyperkalemia in patients with chronic kidney disease, diabetes and heart failure.